Condition: Breast Neoplasms · HER2-positive Breast Cancer · Circulating Tumor Cell · Sponsor: AC Camargo Cancer Center
Phase II unicentric randomized trial which will include early HER2 positive breast cancer patients, candidate to neoadjuvant therapy with trastuzumab and pertuzumab. Circulating tumor cells will be collected at neoadjuvant therapy baseline. Patients with pathological complete response will be randomized in 1:1 ratio for adjuvant trastuzumab (arm A) versus trastuzumab + pertuzumab (arm B) in a two factorial design: group A, with HER2 positive CTCs and group B, with HER2 negative/absent CTCs.
This description comes directly from the study's public registry record.
Marcelle G Cesca, MD · +551121895000 · marcelle.cesca@accamargo.org.br
Ludmilla TD Chinen, PhD · +551121895000 · ludmilla.chinen@accamargo.org.br
Always discuss trial participation with your own doctor first.
| A.C. Camargo Cancer Center | São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04993014